Related Experiment Video
Updated: Oct 13, 2025
09:36
RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
Published on: April 10, 2018
25.6K
Non-coding RNAs and their bioengineering applications for neurological diseases.
Tuhin Das1,2, Tushar Kanti Das3, Anne Khodarkovskaya4
1Quanta Therapeutics, San Francisco, CA, USA.
Bioengineered
|November 10, 2021
Summary
Bioengineering mammalian non-coding RNAs (ncRNAs) offers new therapeutic avenues for neurological diseases like Alzheimer's and Parkinson's. Engineering these ncRNAs enhances their potential for treating complex brain disorders.
Area of Science:
- Biomedical Engineering
- Molecular Biology
- Neuroscience
Background:
- Cellular biomolecule engineering presents therapeutic opportunities but faces challenges.
- Mammalian ribonucleic acid (RNA) bioengineering is a rapidly advancing field with significant biomedical potential.
- Non-coding RNAs (ncRNAs), including microRNAs and long non-coding RNAs, play regulatory roles and are emerging as therapeutic candidates.
Purpose of the Study:
- To review the emerging repertoire of ncRNAs in neurological diseases.
- To highlight advances in engineering ncRNAs for improved therapeutic feasibility.
- To provide insights into the applications of bioengineered ncRNAs for neurological conditions.
Main Methods:
- Literature review of ncRNA research in neurological diseases.
- Analysis of engineering strategies for ncRNA therapeutics.
- Discussion of current and potential applications of bioengineered ncRNAs.
Main Results:
- ncRNAs are promising therapeutic candidates for neurological diseases such as Alzheimer's, Parkinson's, neuroinflammation, and drug abuse disorders.
- Engineering strategies are being developed to enhance ncRNA biocompatibility and therapeutic efficacy.
- Bioengineered ncRNAs show potential for treating complex neurological conditions.
Conclusions:
- ncRNAs represent a significant frontier in the bioengineering of therapeutics for neurological diseases.
- Continued research into ncRNA engineering will likely lead to novel treatments for debilitating brain disorders.
- The evolving understanding of ncRNAs opens new possibilities for biomedical applications.
Related Concept Videos
02:15Experimental RNAi
6.4K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.4K
02:39lncRNA - Long Non-coding RNAs
9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
01:23Types of RNA
69.4K
Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
69.4K
02:30siRNA - Small Interfering RNAs
17.2K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.2K
02:23RNA Editing
9.3K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.3K
02:47Ribozymes
12.7K
The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can...
Ribozymes can...
12.7K